[New Developments in Drug-eluting Stents]

Overview

Journal Herz

Specialty Cardiology & Vascular Diseases

Date 2011 Apr 20

PMID 21503825

Authors

M Kollum

C Bode

Affiliations

Soon will be listed here.

Abstract

Although the use of balloon catheters or stents for the treatment of coronary artery lesions shows good short-term results, long-term prognosis due to the occurrence of restenosis in 20%-30% of patients is less promising. Thus new techniques and mechanical improvements to balloons and stents are always necessary in order to achieve the best possible results from percutaneous coronary intervention. Drug-eluting stents (DES) have improved the principles of bare metal stents (BMS) by neointimal growth inhibition due to local drug release. DES can significantly reduce the incidence of in-stent restenosis. These benefits and lower costs compared to surgical treatment make the DES a more attractive alternative for the treatment of coronary heart disease. Currently, the CYPHER Sirolimus-eluting stent (SES) by Cordis (approved by the FDA on 24th April 2003), the TAXUS Express and the LIBERTE Paclitaxel-eluting stent (PES) by Boston Scientific (approved by the FDA on 4th March 2004 and October 10, 2008), the Endeavor Zotarolimus-eluting stent (ZES) by Medtronic (approved by the FDA on 1st February 2008) and the Xience V Everolimus-eluting stent (EES) by Abbott Vascular (approved by the FDA on 2nd July 2008) are approved in the US. Following approval of the Cypher and Taxus stents, the clinical data indicated a slightly higher incidence of stent thrombosis (ST) as compared to the pure BMS after implantation. The present article discusses the main clinical trials and design developments in DES currently available and takes a prospective look at future technologies in the field of DES.

References

Stone G, Ellis S, Cannon L, Mann J, Greenberg J, Spriggs D . Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005; 294(10):1215-23. DOI: 10.1001/jama.294.10.1215. View

Nikolsky E, Lansky A, Sudhir K, Doostzadeh J, Cutlip D, Piana R . SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Am Heart J. 2009; 158(4):520-526.e2. DOI: 10.1016/j.ahj.2009.07.025. View

Regar E, Sianos G, Serruys P . Stent development and local drug delivery. Br Med Bull. 2002; 59:227-48. DOI: 10.1093/bmb/59.1.227. View

Spuentrup E, Ruebben A, Mahnken A, Stuber M, Kolker C, Nguyen T . Artifact-free coronary magnetic resonance angiography and coronary vessel wall imaging in the presence of a new, metallic, coronary magnetic resonance imaging stent. Circulation. 2005; 111(8):1019-26. DOI: 10.1161/01.CIR.0000156462.97532.8F. View

Claessen B, Beijk M, Legrand V, Ruzyllo W, Manari A, Varenne O . Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial. Circ Cardiovasc Interv. 2009; 2(4):339-47. DOI: 10.1161/CIRCINTERVENTIONS.108.831800.108.831800. View

Ormiston J, Serruys P, Regar E, Dudek D, Thuesen L, Webster M . A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008; 371(9616):899-907. DOI: 10.1016/S0140-6736(08)60415-8. View

Barragan P, Rieu R, Garitey V, Roquebert P, Sainsous J, Silvestri M . Elastic recoil of coronary stents: a comparative analysis. Catheter Cardiovasc Interv. 2000; 50(1):112-9. DOI: 10.1002/(sici)1522-726x(200005)50:1<112::aid-ccd25>3.0.co;2-x. View

Costa Jr J, Abizaid A, Costa R, Feres F, Tanajura L, Abizaid A . 1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial. JACC Cardiovasc Interv. 2009; 2(5):422-7. DOI: 10.1016/j.jcin.2009.02.009. View

Kedhi E, Stone G . Everolimus-eluting stents: insights from the SPIRIT IV and COMPARE trials. Expert Rev Cardiovasc Ther. 2010; 8(9):1207-10. DOI: 10.1586/erc.10.96. View

10.

Ormiston J, Abizaid A, Spertus J, Fajadet J, Mauri L, Schofer J . Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions. Circ Cardiovasc Interv. 2010; 3(6):556-64. DOI: 10.1161/CIRCINTERVENTIONS.110.946426. View

11.

Stone G, Ellis S, Cox D, Hermiller J, OShaughnessy C, Mann J . A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004; 350(3):221-31. DOI: 10.1056/NEJMoa032441. View

12.

Tada N, Virmani R, Grant G, Bartlett L, Black A, Clavijo C . Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ Cardiovasc Interv. 2010; 3(2):174-83. DOI: 10.1161/CIRCINTERVENTIONS.109.877522. View

13.

Chevalier B, Silber S, Park S, Garcia E, Schuler G, Suryapranata H . Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2. Circ Cardiovasc Interv. 2009; 2(3):188-95. DOI: 10.1161/CIRCINTERVENTIONS.108.823443. View

14.

Ruef J, Storger H, Schwarz F, Haase J . Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions. Catheter Cardiovasc Interv. 2008; 71(3):333-9. DOI: 10.1002/ccd.21326. View

15.

Hoffmann R, Jansen C, Konig A, Haager P, Kerckhoff G, Vom Dahl J . Stent design related neointimal tissue proliferation in human coronary arteries; an intravascular ultrasound study. Eur Heart J. 2001; 22(21):2007-14. DOI: 10.1053/euhj.2001.2606. View

16.

Schampaert E, Cohen E, Schluter M, Reeves F, Traboulsi M, Title L . The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004; 43(6):1110-5. DOI: 10.1016/j.jacc.2004.01.024. View

17.

Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann F . Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation. 2001; 103(23):2816-21. DOI: 10.1161/01.cir.103.23.2816. View

18.

Serruys P, Silber S, Garg S, van Geuns R, Richardt G, Buszman P . Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010; 363(2):136-46. DOI: 10.1056/NEJMoa1004130. View

19.

Weisz G, Leon M, Holmes Jr D, Kereiakes D, Clark M, Cohen B . Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol. 2006; 47(7):1350-5. DOI: 10.1016/j.jacc.2005.11.077. View

20.

Waksman R, Pakala R, Kuchulakanti P, Baffour R, Hellinga D, Seabron R . Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheter Cardiovasc Interv. 2006; 68(4):607-17. DOI: 10.1002/ccd.20727. View